3 Healthcare Stock Stories Making Chatter Before the Weekend

Pfizer (NYSE:PFE): Closing price $28.53

On Friday, Pfizer said that the FDA has accepted for review a supplemental new drug application for the Xenjanz (tofacitinib citrate) rheumatoid arthritis indication requesting expansion of the label to include inhibition of progression of structural damage. The agency will review the sNDA and is expected to provide a decision by February next year, based on the anticipated Prescription Drug User Fee Act action date for the sNDA. In November 2012, Xeljanz 5 mg twice daily was approved by the FDA for the treatment of adults having moderately to severely active RA, who saw an inadequate response or intolerance to methotrexate, and is the first approved RA treatment in a new class of medicines that are known as Janus kinase inhibitors.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Amarin Corporation (NASDAQ:AMRN): Closing price $6.29

Amarin reported on Friday the results from a Phase 1 clinical trial that compared bioavailability of components from a fixed-dose combination of its flagship product, Vascepa (icosapent ethyl), plus rosuvastatin, to a linked administration of the two agents independently, and to rosuvastatin alone. Amarin is a biopharmaceutical firm focused on the commercialization and development of therapeutics through which to improve cardiovascular health.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMRN

Jazz Pharmaceuticals (NASDAQ: JAZZ): Closing price $67.07

On Friday, Brean Capital kept its Buy on Jazz shares, and raised its price target from $88 to $93. Analyst Gene Mack remarked that a recent update from management increased his confidence, saying that ”We are increasing our revenue and earnings estimates for fiscal year 2013 to $870 million from $823 million and $6.25 from $5.87. The increase represents the high end of fiscal year 2013 earnings per share guidance range of $6.10 to 6.30 and comes mainly from increasing our Erwinaze estimate from $200 million to $225 million.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JAZZ

Don’t Miss: Will Young People Jeopardize the Success of Obamacare?